The Role of New Oral Anticoagulants (NOACs) in Cancer Patients

Adv Exp Med Biol. 2017:906:137-148. doi: 10.1007/5584_2016_112.

Abstract

New oral anticoagulants (NOACs) are likely to have a major impact in the next few years, changing clinical practice of anticoagulation therapy. Evidence on its efficacy and superiority to vitamin K antagonists (VKAs) in treating non-cancer patients have been reported in a few clinical trials. However, patients with cancer are complicated by the prothrombotic nature of the disease, need for potentially invasive surgery and interventions, and altered drug handling. This chapter examines the available evidence and guidelines on the use of NOAC in patients with cancer.

Keywords: Cancer; Deep venous thrombosis; Direct oral anticoagulants; New oral anticoagulants; Pulmonary embolism; Venous thromboembolism.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Anticoagulants / therapeutic use*
  • Antithrombins / therapeutic use
  • Catheters, Indwelling
  • Dabigatran / therapeutic use
  • Drug Administration Schedule
  • Drug Dosage Calculations
  • Humans
  • Neoplasms / complications
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Pyrazoles / therapeutic use
  • Pyridines / therapeutic use
  • Pyridones / therapeutic use
  • Randomized Controlled Trials as Topic
  • Rivaroxaban / therapeutic use
  • Thiazoles / therapeutic use
  • Venous Thromboembolism / complications
  • Venous Thromboembolism / drug therapy*
  • Venous Thromboembolism / pathology
  • Venous Thrombosis / complications
  • Venous Thrombosis / drug therapy*
  • Venous Thrombosis / pathology

Substances

  • Anticoagulants
  • Antithrombins
  • Pyrazoles
  • Pyridines
  • Pyridones
  • Thiazoles
  • apixaban
  • Rivaroxaban
  • Dabigatran
  • edoxaban